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Tumor-initiating cells (T-ICs) are a subpopulation of
chemoresistant tumor cells that have been shown
to cause tumor recurrence upon chemotherapy.
Identification of T-ICs and their related pathways
are therefore priorities for the development of new
therapeutic paradigms. We established chemore-
sistant hepatocellular carcinoma (HCC) xenograft
tumors in immunocompromisedmice in which an en-
riched T-IC population was capable of tumor initia-
tion and self-renewal. With this model, we found
CD24 to be upregulated in residual chemoresistant
tumors when compared with bulk tumor upon
cisplatin treatment. CD24+ HCC cells were found to
be critical for the maintenance, self-renewal, differ-
entiation, and metastasis of tumors and to signifi-
cantly impact patients’ clinical outcome. With a lenti-
viral-based knockdown approach, CD24 was found
to be a functional liver T-IC marker that drives T-IC
genesis through STAT3-mediated NANOG regula-
tion. Our findings point to a CD24 cascade in liver
T-ICs that may provide an attractive therapeutic
target for HCC patients.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in the world (Jemal et al., 2008). The first-line treatment
for HCC is liver transplantation or surgical resection (Carr,
2004; Kassahun et al., 2006). However, most HCCs are inoper-
able because patients present at advanced stages. Even after
surgical resection, the long-term prognosis of HCC remains
unsatisfactory due to high recurrence rates. For HCC patients
in advanced stages, chemotherapy via either transarterial che-
moembolization or a systemic route is the second-line treatment.
Unfortunately, the overall response rate is unsatisfactory due to
the highly chemoresistant nature of the tumor and the toxicity of
the chemotherapeutic agents (Aguayo and Patt, 2001; Llovet
and Bruix, 2003; Kuvshinoff and Ota, 2002). Further investigation50 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.into the mechanism of chemoresistance of HCCs is needed to
improve the survival rate.
The cancer stem cell hypothesis posits that cancers are main-
tained in a hierarchical organization of rare ‘‘cancer stem cells’’
(or tumor-initiating cells, T-ICs), which divide rapidly into ampli-
fying cells and differentiated tumor cells (Dalerba et al., 2007).
Owing to this unique survival mechanism, this rare population
of cells is resistant to the current chemotherapies (Al-Hajj,
2007). This hypothesis also provides an explanation for the
failure of current treatment regimes due to the fact that they
are largely targeted at eradicating the rapidly proliferating tumor
bulk. The existence of T-ICs was first evidenced in acutemyeloid
leukemia (Lapidot et al., 1994) andmore recently in different solid
tumors, including those of the brain (Singh et al., 2003), colon
(O’Brien et al., 2007), breast (Al-Hajj et al., 2003), prostate
(Collins et al., 2005), melanoma (Fang et al., 2005), and pancreas
(Hermann et al., 2007). Integrative comparative genomic analysis
has established molecular similarities between T-ICs and normal
tissue stem cells, suggesting a role for liver T-ICs in hepatocar-
cinogenesis (Marquardt and Thorgeirsson, 2010). Recently, liver
T-ICs have been identified by several cell surface antigens such
as CD133 (Ma et al., 2007, 2010), CD90 (Yang et al., 2008), and
EpCAM (Yamashita et al., 2009), and these T-ICs are capable of
self-renewal andwere found to be resistant to chemotherapeutic
drugs (Ma et al., 2008).
Because T-ICs are relatively resistant to chemotherapy, we
enriched for liver T-ICs by establishing chemoresistant HCC
xenograft tumors in immunocompromised mice, mimicking the
clinical situation under which HCC patients receive chemo-
therapy. With this model, we identified CD24, a mucin-like cell
surface glycoprotein, to be upregulated in residual chemoresist-
ant tumors upon cisplatin treatment when compared with
untreated tumors. To further investigate the role of CD24+ cells
in HCC, we isolated these cells from the HCC cell lines PLC/
PRF/5 and HLE and HCC clinical samples. Freshly isolated
CD24+ cells were found to be more quiescent, with a greater
ability to form tumors in NOD/SCID mice, and an ability to self-
renew, differentiation, and metastasis. The clinical impact of
CD24 was also addressed, and it was found to significantly
correlate with aggressive tumor behavior. Knockdown of CD24
by a lentiviral-based shRNA approach suppressed the stem/
progenitor cell characteristics, suggesting that CD24 is a func-
tional marker of liver T-ICs. Furthermore, we identified NANOG
Figure 1. Upregulation of CD24 in Self-Re-
newing Liver Cancer Cells in Chemoresist-
ant HCC Xenograft Model
(A) Nude mice with xenograft tumors of 4 mm
in diameter were separated into four groups
and given different dosages (1 mg/kg, 2 mg/kg,
5 mg/kg, and no-drug control) of cisplatin at
embedded intervals of 4 days for 4 weeks.
(B) The dosage of 5mg/kgwas found to be optimal
to achieve enrichment of chemoresistant cells,
because further administration of drug fromday 14
onward did not cause significant shrinkage of
the tumors, indicating that the majority of cells
remaining in the small tumors were insensitive to
cisplatin.
(C) When the cells dissociated from the ‘‘resistant
group’’ and ‘‘untreated group’’ tumors were in-
jected orthotopically into secondary SCID mice
recipients, 5 3 104 cells from the resistant group
were sufficient to form tumors, whereas no tumors
were formed from the untreated group cells.
(D) By qPCR, it was shown that CD24was 2.9-fold
higher in the PLC/PRF/5-derived resistant group
tumor cells.
(E) Similarly, higher expression of CD24 at the
protein level was shown by IHC analysis of
paraffin-embedded tumor tissue. CD24 positivity
in the PLC/PRF/5 and Huh-7-derived tumor was
found to be increased in the chemoresistant
group when compared with the untreated group.
See also Figure S1.
(F) By FACS analysis, it was found that MIHA,
a nontumorigenic liver cell line, did not express
CD24, whereas the HCC cell lines tested varied in
their expression levels, ranging from 6.4% ± 2.6%
in MHCC-97L to 97.7% ± 1.5% in Huh-7 cells.
(G and H) By IHC, it was shown that in clinical
specimens, the nontumorous liver tissues away
from the HCC tumors stained negative for CD24,
whereas in the tumorous tissues the expression of
CD24 was scarce (29/41, i.e., 70.7% of cases
examined had <2% positivity) and usually in few
isolated cells. Error bars represent standard
deviation (SD) from at least three independent
experiments.
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tumorigenicity and self-renewal. cDNA microarray analysis re-
vealed that regulation of NANOG by CD24 was STAT3 depen-
dent. Our findings may provide an attractive therapeutic
approach of targeting the CD24 cascade in liver T-ICs to achieve
better clinical outcomes for HCC patients.
RESULTS
CD24Was Elevated in Self-Renewing Liver Cancer Cells
Enriched by Chemotherapy in an HCC Xenograft Model
According to the ‘‘cancer stem cell’’ hypothesis, chemotherapy
reduces the tumor burden while sparing a T-IC populationCell Stem Cell 9,endowed with drug-resistant properties
(Ma et al., 2008; Pardal et al., 2003). In
order to determine whether liver T-ICs
are enriched upon chemotherapy, a che-moresistant xenograft model derived from HCC cell lines was
established that mimics the heterogeneity observed in patients’
tumors. Tumor xenografts derived from PLC/PRF/5 cells were
subcutaneously inoculated into nude mice. When the tumors
reached 4 mm in diameter, the mice were injected intraperitone-
ally with various doses of cisplatin. Such treatment resulted in
variable tumor inhibition among the xenografts (Figure 1A). The
dosage of cisplatin for establishment of chemoresistant tumor
was determined experimentally by comparing the tumor res-
ponse to several different dosages ranging from 1 mg/kg to
5 mg/kg. From the dose response curve, 5 mg/kg was chosen
as the level at which further increase of cisplatin concentration
did not further reduce the tumor size (Figure1B). To verifywhether50–63, July 8, 2011 ª2011 Elsevier Inc. 51
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residual chemoresistant tumor, single HCC cells derived from
untreated (control group) and chemoresistant residual (chemore-
sistant group) tumors were isolated. The tumorigenicity of the
HCC cells derived from these two groups was compared after
serial orthotopic transplantation of 5 3 104 corresponding cells
into SCID mice. Because the PLC/PRF/5 cells were labeled with
the luciferasegene, the tumorigenicitywasevaluatedwithaxeno-
gen imaging system. Compared with HCC cells from untreated
tumor, enhanced tumor-forming and self-renewal abilities were
observed in chemoresistant residual HCC cells, indicating suc-
cessful enrichment for liver T-ICs in this chemoresistant HCC
xenograft model derived from PLC/PRF/5 cells (Figure 1C). To
further determine which markers are elevated in self-renewing
chemoresistant HCC cells, the messenger RNA profiles from
tumors derived from the untreated and chemoresistant groups
(5 mg/kg) were compared with a cDNA microarray containing
34,000 genes (data not shown). CD24, but not other currently
known liver T-ICmarkers (CD133,CD90, andEpCAM),was found
to be upregulated by 2-fold in the chemoresistant group com-
pared to the control group. To validate this observation, we
studied the expression of CD24 by qPCR and immunohisto-
chemistry (IHC) in the tumors. Consistent with the cDNAmicroar-
ray data, CD24 was found to be upregulated by 3-fold by qPCR
(Figure 1D). Similarly, IHCstudies also showed thatCD24 expres-
sion was dramatically higher in the chemoresistant group relative
to the control group (Figure 1E). To exclude the possibility of a cell
type-specific effect, CD24 expression was further evaluated in
the same chemoresistant model with another HCC cell line,
Huh-7.By IHCstaining,CD24expressionwasdramatically higher
in the chemoresistant group (see Figure S1 available online).
CD24 Expression in HCC Cell Lines and Human HCC
Specimens
To determine whether CD24 marks more tumorigenic liver cells,
we examined its expression by flow cytometry (FACS) analysis
in apanel of liver cell lines, including the nontumorigenic immortal-
ized cell line MIHA and the HCC cell lines Huh-7, Hep3B,
BEL7402, PLC/PRF/5, HLE, BEL7402, MHCC-97L, MHCC-97H,
and MHCC-LM3. Variable expression of CD24 was found in the
HCC cell lines with in vivo tumor forming ability. In contrast, the
immortalized nontumorigenic cell line MIHA, which is incapable
of tumor formation in vivo, showed no CD24 expression (Fig-
ure 1F). These results suggest that CD24 expression might play
a role in tumor development in vivo. Next, we asked whether
CD24 was overexpressed in patient HCC specimens when
compared with nontumor counterparts. We performed IHC stain-
ing for CD24 on 41 human HCC tissue samples as well as their
nontumor counterparts. The percentage of CD24+ cells in the
HCC specimens ranged from 0% to 16%, whereas there was no
CD24 expression in the nontumor counterparts. Among all HCC
specimens, more than 70% (29/41) of the cases showed CD24
expression in less than 2% of cells (Figures 1G and 1H). Thus,
CD24 was expressed sporadically in human HCC specimens.
CD24+ HCC Cells Possessed Characteristics
of Stem/Progenitor Cells
T-ICs are believed to possess the stem/progenitor properties of
relative quiescence (Friel et al., 2008), self-renewal (Patrawala52 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.et al., 2005), and tumorigenicity (Li et al., 2007) in immunodefi-
cient mice. First, we determined whether CD24+ HCC cells
were more tumorigenic than their CD24 counterparts in vivo
by tumor-forming assay with CD24+ and CD24 cells purified
from PLC/PRF/5 and HLE cell lines. Purified cells were inocu-
lated subcutaneously into NOD/SCID mice. A significant differ-
ence in tumor incidence was observed between CD24+ and
CD24 cells (Figures 2A and 2B). As few as 500 CD24+ cells
were sufficient for consistent tumor development in NOD/SCID
mice (Tables S1A and S1B). A key property of stem cells,
including T-ICs, is their unique ability to undergo self-renewal
(Patrawala et al., 2005). One method of evaluating self-renewal
capacity is by testing serial passage ability. After xenografts
derived from sorted PLC/PRF/5 cells formed, the corresponding
tumors were excised from the primary recipients, dissociated
into a single-cell suspension, grown in culture for approximately
1 week, resorted into CD24+ and CD24 cells using an antibody
specific to human CD24, and then reinjected into secondary
mouse recipients. After 3 weeks, all the secondarily xenografted
mice injected with CD24+ cells showed tumor formation that re-
constituted the phenotypic heterogeneity of the primary xeno-
grafts (Figures 2A and 2B), providing direct evidence of the
self-renewal ability of the cell population. Consistently, as few
as 500 CD24+ cells were sufficient for tumor formation (Table
S1C). In addition, all secondary xenografts formed around
3 weeks, a significantly shorter tumor latency period than for
the primary xenografts. Normal and neoplastic stem-like cells
from epithelial organs can be expanded as sphere-like aggre-
gates in serum-free EGF-bFGF-supplemented medium and
undergo serial passage (Liu et al., 2005). To obtain further
evidence for the self-renewal ability of CD24+ cells, we per-
formed a sphere formation assay. Compared with CD24 cells,
significantly larger and more hepatospheres were observed in
CD24+ cells isolated from both PLC/PRF/5 and HLE cells (Fig-
ure 2C), which supports the greater self-renewal capability of
CD24+ HCC cells. It is believed that quiescence is one of the
characteristics of stem cells (Friel et al., 2008). To compare the
relative quiescence of CD24+ and CD24 cell fractions, cell
proliferation rate was measured. Colony formation assay re-
vealed that CD24+ cells derived from PLC/PRF/5 and HLE prolif-
erated at a significantly lower rate than CD24 cells (p < 0.010
and p < 0.001, respectively, t test, Figure 2D). Finally, we ad-
dressed whether CD24+ cells had other intrinsic properties of
stem cells by examining the expression of certain ‘‘stemness’’-
associated genes that are crucial in pathways and programs
that establish and maintain stem cell-like characteristics. With
qPCR analysis, we found that CD24+ fractions purified from
both PLC/PRF/5 and HLE cells had a general overexpression
of these genes (Figure 2E).
Clinical Significance of CD24 in HCC
We have demonstrated that sorted CD24+ cells derived from
HCC cell lines possess stem/progenitor characteristics (Fig-
ure 2). To examine the role of CD24+ HCC cells in HCC patients,
we isolated single HCC cells from fresh HCC clinical samples
and separated them into CD24+ and CD24 cell populations.
We examined whether CD24+ HCC cells derived from HCC clin-
ical samples also possessed tumorigenicity and self-renewal
ability. In colony formation assays, CD24+ HCC cells were able
Figure 2. CD24+ HCC Cells Possessed Traits of Stem/Progenitor Cells
(A) Representative images of the primary-sorted PLC/PRF/5 and HLE and secondary PLC/PRF/5 cell-induced tumor formation. See also Table S1. Right flanks
were injected with CD24+ cells while left flanks were injected with CD24 cells. Red arrow indicates the site of tumor formation for HLE cells.
(B) Paraffin-embedded tissue of the xenotransplanted tumors were processed for H&E staining and IHC to detect CD24 expression. These representative images
show that in cases of tumor formation, tumor cell heterogeneity, in terms of both cell morphology and CD24 expression, was observable.
(C) By sphere forming assay, the in vitro self-renewal ability was enhanced in CD24+ cells from PLC/PRF/5 and HLE (left). Secondary spheres formed from
dissociating both spheres also demonstrated enhanced serial sphere-forming capacity in CD24+ cells, respectively (right).
(D) By colony formation assay on the sorted cells of PLC/PRF/5 and HLE, it was demonstrated that CD24+ HCC cells had a significantly lower proliferation rate
when compared with CD24 cells, respectively (*p < 0.010 and *p < 0.001, respectively, t test).
(E) CD24+ cells from the two HCC cell lines, PLC/PRF/5 and HLE, overexpressed several genes related to stemness when compared to CD24 cells (*p < 0.05;
**p < 0.01). Error bars represent standard deviation (SD) from at least three independent experiments.
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Figure 3. Clinical Relevance of CD24 Expression
(A) When cells from a fresh clinical HCC sample (patient #38) were sorted magnetically into CD24+ and CD24 fractions, the CD24+ cells displayed significantly
enhanced anchorage-independent growth in the soft-agar colony formation assay, indicating higher in vitro tumorigenicity.
(B) As few as 4000 CD24+ HCC cells (4/4) from two clinical HCCs induced tumor formation. Right flanks were injected with CD24+ cells while left flanks were
injected with CD24 cells. Red arrows indicate the site of tumor formation.
(C) Paraffin-embedded tissues of the xenotransplanted tumors were processed for H&E staining and IHC to detect CD24 expression.
(D) CD24+ cells from primary HCC samples overexpressed several genes related to stemness when compared with CD24 cells (*p < 0.05; **p < 0.01).
(E) By sphere forming assay, the in vitro self-renewal ability was enhanced in CD24+ cells from fresh HCC tumor (patients #36, #38 and #51).
(F) Kaplan-Meier curves for disease-free and overall survival were compared according to the CD24 expression in tumor tissues. The overall and disease-free
survival of HCC patients with CD24 overexpression in their tumors were 36.7 and 6.6 months as compared with 94.2 and 42.4 months in patients with low CD24
expression (p = 0.113 and 0.002, respectively, log-rank test).
Error bars represent standard deviation (SD) from at least three independent experiments.
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terparts (p < 0.001, t test) (Figure 3A), and this showed that
CD24+ HCC cells were more tumorigenic than CD24 cells
in vitro. To evaluate the in vivo tumorigenicity, two fresh HCC
patient samples were used. By flow cytometry, corresponding
CD24+ andCD24 cells were sorted frompatient #71 and patient
#73, and their CD24 expression was found to be 15% and 2%,
respectively. As few as 4000 CD24+ HCC cells are able to
develop a tumor in NOD/SCID mice, while there was no tumor
formation with CD24 cells after 70 days of tumor inoculation
(Figures 3B and 3C). The capacity of CD24+ cells for self-renewal
was also evidenced by sphere formation assays and evaluation
of stemness genes by quantitative PCR. CD24+ HCC cells
preferentially expressed stemness genes and were able to54 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.survive in anchorage-independent serum-free EFG-FGF supple-
mented medium (Figures 3D and 3E). CD24 expression was
previously found to be overexpressed in HCC and has prog-
nostic significance (Huang and Hsu, 1995; Yang et al., 2009).
Next, we investigated the potential relationship between CD24
expression and the clinical outcome of HCC patients. We retro-
spectively analyzed the CD24 expression in 46 HCC patients by
quantitative PCR. The cut-off value of T/N > 3 was used to deter-
mine CD24 expression in HCC patients. Eighteen (39.1%) of the
46 cases showed more than 3-fold CD24 overexpression in the
HCC tumor tissues as compared with the corresponding non-
tumorous liver tissues, and th ese were considered the high
CD24 expression group. The correlation between CD24 overex-
pression and the clinico-pathologic features is summarized in
Table 1. Clinico-Pathologic Correlation of CD24 Expression in
HCC Patients
CD24
Overexpression
Clinico-Pathological Variables %3-fold >3-fold p Value
Recurrence in the First Year (n = 46)
No 22 6 0.002a,b
Yes 6 12
Venous Infiltration (n = 43)
Absence 19 3 0.003a,b,c
Presence 9 12
Serum AFP Level (n = 36)
Low (%20 ng/ml) 16 4 0.009a,b,c
High (>20 ng/ml) 6 10
TNM Stage (n = 43)
Early stage (I-II) 15 2 0.010a,b,c
Late stage (III-IV) 13 13
Microsatellites (n = 46)
Absence 23 10 0.051b
Presence 5 8
Age (n = 46)
Young (%median, 54) 13 12 0.179b
Old (>median, 54) 15 6
Differentiation Status (n = 36)
Well differentiated 7 3 0.456c,d
Moderately to poorly differentiated 13 13
Tumor Size (n = 45)
Small (%5 cm) 14 7 0.565b,c
Large (>5 cm) 14 10
HBV Association (n = 46)
Negative of HBsAg 11 8 0.729b
Positive of HBsAg 17 10
aSignificant difference.
bc2 test.
c Total number < 46 due to missing data.
d Fisher’s exact test.
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a significantly higher risk of tumor recurrence in the first year after
surgery (p = 0.002,c2 test) and higher serumAFP level (p = 0.009,
c2 test). Their tumors more frequently had venous infiltration
(p = 0.003, c2 test) and they presented at advanced tumor stages
(p = 0.010, c2 test). Patients with CD24 overexpression in their
tumors had significantly shorter disease-free survival than those
with low CD24 expression (p = 0.002, log-rank test) (Figure 3F).
Consistently, patients with CD24 overexpression had shorter
overall survival, though this did not reach statistical significance
(p = 0.113, log-rank test) (Figure 3F). All in all, CD24 overexpres-
sion in HCC correlated with more aggressive tumor behavior
and worse clinical outcome.
CD24+ HCC Cells Had the Capacity to Metastasize
In Vivo
Venous infiltration is an important pathologic feature determining
HCC metastasis and tumor recurrence (Arii et al., 1992). Asshown in Table 1, high CD24 expression significantly correlated
with venous infiltration. This finding suggests that CD24+ cells
are endowed with metastatic features. To test this hypothesis,
we first isolated CD24+ and CD24 cells from PLC/PRF/5 and
examined their invasive and migratory abilities by using matrigel
invasion and transwell migration assay, respectively. Prior to
each experiment, trypan blue assay was performed to show
that cell viability of sorted cells from both subpopulations was
greater than 90% (data not shown). As compared toCD24 cells,
CD24+ cells displayed approximately 3.7-fold and 5-fold higher
cell migration and invasion efficiency, respectively (p < 0.001, t
test) (Figures 4A and 4B). To test the in vivo metastatic role of
CD24+ cells, an experimental metastasis model was employed
in which 1 3 105 CD24+ or CD24 cells were injected into
NOD/SCID mice through tail vein injection. After 40 days, the
formation of tumor foci in the lungswas evaluatedwith a xenogen
imaging system. Three out of five (60%) mice injected with
CD24+ cells showed tumor formation in the lungs, whereas
none of themice injected with CD24 cells showed tumor forma-
tion in the lungs (Figures 4C and 4D). In addition, lung metastasis
was also observed in NOD/SCID mice after subcutaneous injec-
tion of CD24+ derived from patients #71 and #73 (Figure S2A).
Histological evidence for the lack of tumorigenicity in NOD/
SCID mice inoculated with CD24 cells is shown in Figure S2B.
These data support the hypothesis that CD24+ T-ICs represent
a distinct invasive T-IC population that contributes to tumor
metastasis. Recent studies have suggested that CD133 and
EpCAM are putative T-IC markers for HCC (Ma et al., 2007;
Yamashita et al., 2009). By flow cytometric analysis, we exam-
ined and compared the expression of each marker in Huh-7
cells. CD24 expression was found to overlap with that of
CD133 and EpCAM, suggesting that these three markers share
similar self-renewal pathways (Figure S3A). Contrary to CD133
and EpCAM, we observed only a very low, if at all, overlapping
expression between CD24 and CD90 (1%) (data not shown).
In view of this, we proceeded to examine whether CD24 serves
a unique function of liver T-IC over CD90 by using a CD90 lenti-
viral based shRNA knockdown approach in MHCC97H cells,
which was found to contain the highest CD24 expression
among a panel of liver cell lines tested (Yang et al., 2008).
CD90-repressed clones (shRNA CD90) or CD90-expressing
clones (nontarget control) were first sorted for CD24+ and
CD24 cells and then examined for differential tumorigenic
capacity (Figure S3B). CD24+ liver T-ICs were found to be
more tumorigenic than CD24 non-T-ICs. Further, the ability of
CD24+ CD90-expressing or knockdown cells to initiate tumor
formation were very similar, with a tumor initiation rate of
83.3% and 75%, respectively (Figure S3C). Thus, we concluded
that CD24 do serve as a unique function in the T-ICs of HCC.
CD24+ HCC Cells Had the Capacity to Differentiate
In Vitro
To investigate the differentiation capacity of CD24+ cells, we first
cultivated the cells dissociated from fresh HCC clinical tissues in
such specified medium as ‘‘hepatospheres’’ to obtain undiffer-
entiated cells. These hepatospheres were serially passaged by
trypsinization into single cells to reform new hepatospheres
and, after three passages, all the floating hepatospheres were
observed to be CD24+ (data not shown), suggesting the inabilityCell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc. 55
Figure 4. CD24+ HCC Cells Had the
Capacity to Differentiate and Metastasize
In Vivo
(A and B) Using trans-well migration and invasion
assays, it was shown that the CD24+ fraction of
sorted PLC/PRF/5 cells had enhanced migratory
(*p < 0.001, t test) and invasive (*p < 0.001, t test)
properties in vitro.
(C and D) By experimental metastatic assay in
NOD/SCID mice which was evaluated by biolu-
minescent imaging, it was found that CD24+ PLC/
PRF/5 cells injected intravenously successfully
colonized the lungs in three of five mice, whereas
the CD24 cells did not colonize, indicating
enhanced in vivo metastatic ability.
(E) By immunofluorescence staining, spheres of
stem-like cells derived from clinical HCC cells
displayed strong expression of CD24, and CD24
expression (green color) was lost and CK18
(marker for differentiated hepatoyctes; red color)
was gained near peripheral region upon differen-
tiation. The cells are counterstained with DAPI.
(F and G) By comparing the gene expression of
spheres of stem-like cells with their differentiated
progenies, it was found that, for both PLC/PRF/5
cell line and clinical HCC cells (patient #3), CD24
expression was relatively higher in the spheres
than in the parental cells. The stemness of the
spheres was also reflected by the overexpression
of several stemness-associated genes.
(H) Upon culture in serum-containing medium for
2 weeks, FACS-sorted CD24+ PLC/PRF/5 cells
gradually reconstituted the original proportion of
CD24-expressing cells, whereas CD24 cells
failed to give rise to the original heterogeneity of
CD24 expression. Error bars represent standard
deviation (SD) from at least three independent
experiments.
See also Figures S2–S4.
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the differentiation potential of CD24+ cells, hepatospheres
were cultivated without EGF or FGF in the presence of 10%
serum. After 1 day of culture, floating undifferentiated cells
attached to the glass, gradually flattened out from the hepato-
spheres, and became large and adherent cells. Upon differenti-
ation, the hepatospheres gained CK18 expression and lost CD24
expression, and they acquired a morphology closely resembling
the HCC cells present in the original tumor (Figure 4E). By qPCR,
we found consistent decline in CD24 and stemness-associated
genes upon differentiation of the hepatospheres derived from
HCC patient samples (Figure 4F). The same phenomenon was
observed upon differentiation of the hepatospheres derived
from the HCC cell line PLC/PRF/5 (Figure 4G). To further explore56 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.the capacity of CD24+ cells to dif-
ferentiate, highly purified CD24+ and
CD24 cells were separately cultured in
10% serum-supplemented medium for
2 weeks, after which the expression of
CD24 was analyzed in each population
by flow cytometry. We found that the
CD24+ proportion dramatically declinedafter 3 days, and reverted almost to the presorting level, whereas
CD24 cells retained low expression of CD24 even after 2weeks,
indicating that CD24 cells arose only from CD24+ cells and not
vice versa (Figure 4H). In addition, by single cell sorting, increase
in CK18 expression was observed in CD24+ cells but not in
CD24 cells upon differentiation (Figure S4).
CD24 Knockdown Reduced Stem/Progenitor
Characteristics in HCC Cells
It is yet to be proven whether T-IC cell surface markers are just
physical markers or whether they functionally contribute to the
traits of stem/progenitor cells. Therefore, we performed a
CD24 knockdown experiment with a lentiviral-based approach
in cells that highly express CD24 (Huh-7 and PLC/PRF/5). After
Figure 5. CD24 Knockdown Reduced Char-
acteristics of Liver T-ICs
(A and B) Knockdown of CD24 in Huh-7 and PLC/
PRF/5 cells resulted in downregulation of several
genes related to stemness as compared to the
nontarget control (NTC) (*p < 0.05; **p < 0.01, t
test).
(C) CD24 knockdown (shCD24) HCC cells ex-
hibited reduced tumor-forming incidence when
comparedwith NTC cells. See also Table S2. Right
flanks were injected with NTC cells while left flanks
were injected with shCD24 cells. Corresponding
paraffin-embedded tissue of the xenotransplanted
tumors were processed for H&E staining and IHC
to detect CD24 expression.
(D) The effect of CD24 knockdown on tumorige-
nicity of PLC/PRF/5 cells was evaluated with
xenogen bioluminescence imaging. Representa-
tive image of tumor developed from PLC/PRF/5
cells derived from NTC (left) and shCD24 (right)
and corresponding paraffin-embedded tissue of
the xenotransplanted tumors were processed for
H&E staining and IHC to detect CD24 expression.
(E) H&E staining of paraffin-embedded lung tissue
from SCID mice after orthotopic injection of NTC
cells. Black arrows indicate the tumor foci within
the lung tissue.
(F) Knockdown of CD24 in Huh-7 and PLC/PRF/5
cells resulted in significant increase in proliferative
rate, respectively (p = .017 and p = .032, respec-
tively, t test).
(G) Knockdown of CD24 also reduced the size and
number of hepatospheres formed in Huh-7 and
PLC/PRF/5 cells (p < 0.001, t test). In addition,
knockdown of CD24 decreased the ability of cells
to form secondary hepatospheres (p < 0.001,
t test). Error bars represent standard deviation
(SD) from at least three independent experiments.
See also Figure S5.
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reduction (Figures 5A and 5B) in CD24 expression in clones
#121 and #278, respectively, in both Huh-7 and PLC/PRF/5,
we first compared the expression of stemness-associated genes
between CD24 knockdown clones and nontarget controls.
Compared with the nontarget controls, these genes, including
SOX2, OCT4, and NANOG, were downregulated in Huh-7 and
PLC/PRF/5 knockdown clones (#278) (Figures 5A and 5B).
Consistent downregulation of the above stemness genes was
observed in clone #121 (data not shown). Next, we examined
the tumorigenicity of Huh-7 cells upon CD24 knockdown. After
4 weeks, we found that both the number and size of the tumorsCell Stem Cell 9,was lower in clone #278 when compared
with the nontarget control group (Fig-
ure 5C; Table S2). The effect of CD24
knockdown on tumorigenicity was also
examined in PLC/PRF/5 cells. Either
CD24 knockdown cells or control cells
(15,000) were injected into the liver of
SCID mice. The incidence of tumor for-
mation was 60% (3/5) whereas it was
20% (1/5) in the CD24 knockdown group
(Figure 5D). In the control group, all SCID mice showing tumor
formation exhibited lung metastasis. However, no lung metas-
tasis was observed in the CD24 knockdown group, further
suggesting the metastatic role of CD24 in HCC (Figure 5E).
The effect of CD24 knockdown on cell proliferation was also
examined with the colony formation assay. We found that
CD24 knockdown cells proliferated more rapidly than the
nontarget control cells (Figure 5F). The effect of CD24 knock-
down on self-renewal was also examined by sphere formation
assay. We found that CD24 knockdown cells generated fewer
and smaller hepatospheres in their first and second passages
(Figure 5G). In addition, knockdown of CD24 in Huh-7 cells50–63, July 8, 2011 ª2011 Elsevier Inc. 57
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(Figure S5A). Similarly, by cell sorting approach, CD24+ HCC
cells derived from PLC/PRF/5 were more chemoresistant than
CD24 cells (Figure S5B).
CD24 Drove Tumor Initiation and Self-Renewal by
Mediating a Self-Renewal Gene, NANOG
To determine the major downstream mediator of CD24 in tumor
initiation and self-renewal, we scrutinized the qPCR data for
effects of CD24 on stemness-associated genes by both cell
sorting and lentiviral-knockdown approach. The effect of CD24
on the expression of stemness-associated genes in both HCC
cell lines and clinical samples is summarized in Table S3. Among
the genes we examined, NANOG and SOX2 were found to be
consistently altered upon loss of CD24 in the four HCC cell lines
and two HCC clinical samples studied. To further identify the
major mediator of CD24 function, we sought a correlation
between the expression of CD24 with NANOG and SOX2 in
five HCC cell lines that expressed different levels of CD24. In
these five HCC cell lines, CD24 expression positively correlated
with NANOG expression but not with SOX2 (Figure 6A; Fig-
ure S6A). Next, we examined the correlation between CD24
and NANOG by qPCR with the same cohort of HCC patients.
Consistently, CD24 significantly correlated with NANOG ex-
pression in these 46 HCC patient samples (p = 0.026; r = 0.325,
Pearson’s correlation) (Table S4, Figure 6B). To determine
whether CD24 drives tumor initiation and self-renewal by acti-
vating NANOG gene expression, we overexpressed NANOG in
a CD24 knockdown clone (#278) of Huh-7 cells to investigate
whether the effect of CD24 knockdown could be eliminated
upon transfection with NANOG. Using the lentiviral approach,
NANOG was overexpressed in a CD24 knockdown clone
(#278) of Huh-7 cells and the expression level was comparable
to the nontarget control (Figure 6C). After successful confirma-
tion of NANOG overexpression in the CD24 knockdown Huh-7
cells, we compared in SCID mice the tumor-forming abilities of
CD24 knockdown Huh-7 cells with and without NANOG over-
expression. The tumorigenicity of CD24 knockdown cells in-
creased upon NANOG transfection, and it was comparable to
that of the nontarget controls (Figure 6D; Table S5). The effect
of NANOG overexpression on the self-renewal ability of CD24
knockdown Huh-7 cells was also studied via the sphere forma-
tion assay. This revealed that CD24 knockdown cells generated
greater and larger hepatospheres in their first and second
passages upon NANOG overexpression (Figure 6E). This result
provides direct evidence that CD24 mediates tumor initiation
and self-renewal by driving up NANOG expression.
CD24 Regulated NANOG Expression through STAT3
Phosphorylation
Being a transmembrane protein (Sammar et al., 1997), CD24
should be able to transmit extracellular signals to the nucleus
to activate NANOG expression. In order to identify the cyto-
plasmic mediator linking CD24 and NANOG, a cDNA microarray
(the Affymetrix Human genome U133 gene chip) was used to
compare the gene expression profiles of CD24 knockdown
Huh-7 cells and nontarget control cells. By Ingenuity Pathway
analysis, several canonical pathways were identified, among
which ‘‘acute phase response signaling’’ was found to be the58 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.most significantly altered (Figure S6B). One of the key compo-
nents of this signaling cascade is the IL6 pathway, a pathway
important for liver stem cell maintenance, in which phosphoryla-
tion of STAT3 at the tyrosine 705 residue is critical (Lin et al.,
2009; Tang et al., 2008). The pathway analysis suggested the
importance of STAT3 phosphorylation in the IL6 pathway,
because the expression of several genes downstream of Stat3
was altered upon CD24 knockdown (Figure S6C). In embryonic
stem cells, phosphorylated STAT3 was found to bind to the
murine NANOG promoter and activate its transcription (Suzuki
et al., 2006). We therefore hypothesized that CD24 transcrip-
tionally regulated NANOG expression through STAT3 phos-
phorylation. To test this hypothesis, we first examined the
expression of STAT3 and its phosphorylated form in CD24
knockdown clones of Huh-7 and PLC/PRF/5 cells. We found
less phosphorylated STAT3 (Y705) upon CD24 knockdown but
not so for its parental form (Figure 6F); this is consistent with
the cDNA microarray finding that there was no change in the
mRNA level of STAT3. To further examine whether the regulation
of NANOG expression in HCC cells is STAT3 dependent, we
examined pSTAT3 (Y705) and NANOG expression in response
to a STAT3 inhibitor (S3I-201) in PLC/PRF/5 and Huh-7 cells.
NANOG expression was found to be downregulated upon
S3I-201 treatment in a dose-dependent manner (Figure S7A).
This observation was further confirmed when we found that
overexpression of CD24 ORF into CD24-negative cells, MIHA,
resulted in a significant increase in pSTAT3 (Y705) and NANOG
expression, whereas addition of varying doses of S3I-201 led
to abolishment of this effect (Figure S7B). To validate the tran-
scriptional regulation of NANOG by CD24, we transfected
a GFP-tagged NANOG promoter into PLC/PRF/5 cells to
monitor its activity. By FACS sorting, the GFP signal was found
to be notably higher in theCD24+ fraction, reflecting upregulation
of NANOG transcription, and this signal was decreased upon
addition of S3I-201 (Figure 6G). To further examine the potential
binding between phosphorylated STAT3 and the NANOG
promoter, a ChIP-qPCR assay was performed. In Figure 6H,
we demonstrated binding between phosphorylated STAT3 and
NANOG promoters in Huh-7 and PLC/PRF/5 cells. Conversely,
upon CD24 knockdown, there was a decrease of pSTAT3
binding on the NANOG promoters in these two cell lines. CD24
was previously found to be associated with Src-associated
kinase (Sammar et al., 1997), which phosphorylates STAT3
(Byers et al., 2009). By overexpression and knockdown
approaches, activated form of Src (pY416) was consistently
altered but not JAK2, another molecule that has previously
been found to phosphorylate STAT3 (Figures S7C–S7E; Hedvat
et al., 2009), which suggests that CD24 potentially phos-
phorylates STAT3 through Src but not JAK. These findings
demonstrate the positive link between CD24 expression,
STAT3 activation, and NANOG transcription.
DISCUSSION
According to the cancer stem cell hypothesis, T-IC populations
become enriched upon chemotherapy due to their unique
survival mechanism. Recently, this theory has been experimen-
tally proven in various cancer systems including breast and lung
cancer (Bertolini et al., 2009; Yu et al., 2007). In this study, we
Figure 6. CD24 Drove Tumor Formation and Self-Renewal via STAT3-Mediated NANOG Regulation
(A) NANOG expression in different HCC cell lines was evaluated by qPCR and found to significantly correlate with CD24 expression (p = 0.012, r = 0.955,
Pearson’s correlation).
(B) CD24 expression significantly correlated with NANOG expression in 46 HCC patients (p = 0.026, r = 0.325, Pearson’s correlation).
(C) NANOG was successfully transfected in a CD24 knockdown clone (#278) of Huh-7 cells and the expression level was comparable to the nontarget control.
(D) The tumorigenicity of CD24 knockdown cells increased upon NANOG transfection. Representative image of tumor developed from Huh-7 derived from
shCD24 (left) and shCD24-NANOG (right).
(E) In addition, NANOG overexpression in shCD24 knockdown cells also increased the sizes of and number of hepatospheres formed in Huh-7 and PLC/PRF/5
cells (p < 0.001, t test). In addition, NANOG overexpression increased the ability of cells to form primary and secondary hepatospheres in shCD24 cells,
respectively (p < 0.001, t test).
(F) Decreased level of phosphorylated STAT3 (Y705) but not its parental form was observed after CD24 knockdown in Huh-7 and PLC/PRF/5 cells.
(G) Quantitative assessment of GFP-positive cells by flow cytometry for NANOG promoter activity. Flow cytometry analysis showed a 4.5-fold increase in the
percentage of GFP-positive cells in CD24+ PLC/PRF/5 cells when compared with CD24 cells, and its percentage decreased after incubation of S3I-201 at
200 mM. Immunofluorescence staining also revealed increase of GFP signal in CD24+ cells when compared with its CD24 counterpart.
(H) Amarked decrease of pSTAT3 bound on the upstream of transcriptional start site ofNANOGwas found uponCD24 knockdownHuh-7 and PLC/PRF/5 cells as
compared with the corresponding vector control in ChIP assay. Normal rabbit antibody added served as a negative control. Error bars represent standard
deviation (SD) from at least three independent experiments. See also Figures S6 and S7 and Tables S3–S5.
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CD24+ Cells Drive Self-Renewal and Tumor Formationsuccessfully enriched for liver T-ICs using a chemoresistant HCC
xenograft model. In this model, cisplatin-treated HCC cells
showed enhanced self-renewal capacity and tumorigenicity
when compared with untreated control cells. By cDNA microar-
ray, we found that CD24 was upregulated in the enriched T-IC
population, and this was confirmed by qPCR and IHC staining.To eliminate the possibility that upregulation of CD24 upon
chemotherapy was a cell type-specific effect, we confirmed
CD24 upregulation by IHC staining using xenografts derived
from another HCC cell line, Huh-7.
The CD24 gene encodes a heavily glycosylated cell surface
protein anchored to the membrane by phosphatidylinositolCell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc. 59
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CD24+ Cells Drive Self-Renewal and Tumor Formation(Pirruccello and LeBien, 1986). CD24 is an oncogene, which is
overexpressed in various human malignancies (Kristiansen
et al., 2002, 2003). It also plays a role during the embryonal
development of pancreatic cells (Cram et al., 1999). Recent
studies have suggested that CD24 may be a negative T-IC
marker with specific regards to breast cancer (Al-Hajj et al.,
2003). Intriguingly, increasing evidence has shown that CD24+
tumor cells are T-ICs for gastrointestinal cancers such as colon
cancer (Yeung et al., 2010), pancreatic cancer (Li et al., 2007),
and cholangiocarcinoma (Wang et al., 2011). To determine
whether CD24+ cells were liver T-ICs, we isolated CD24+ and
CD24 fractions from HCC cell lines and human HCC samples
by cell sorting. We found that CD24+ HCC cells showed higher
tumorigenicity than their CD24 counterparts in NOD/SCID
mice. In addition, CD24+ HCC cells were capable of self-
renewal, as shown by the fact that they could propagate in
another mouse recipient upon serial transplantation. The self-
renewal ability of CD24+ HCC cells was further evidenced by
the more and larger hepatospheres they generated in sphere
formation assays when compared with their CD24 counterpart.
The above phenotype was also associated with increased
expression of stemness genes. Consistently, CD24+ HCC cells
were found to be more quiescent and to proliferate more slowly
in colony formation assays. Moreover, CD24+ HCC cells were
able to differentiate into CD24 cells but not vice versa by single
cell sorting approach.
To examine whether CD24 was specific for liver T-ICs, we per-
formed CD24 immunostaining of 41 paraffin-embedded HCC
clinical samples and their nontumor counterparts. We found
that only a minority of HCC cells showed CD24 expression,
whereas noCD24 expressionwas observed in the nontumor liver
tissues. Flow cytometric analysis also suggested scanty ex-
pression of CD24 in several fresh HCC clinical samples (data
not shown). Using qPCR on HCC resected specimens, we found
that CD24 overexpression was significantly associated with
shorter disease-free survival of patients. In addition, CD24 over-
expression was significantly correlated with early recurrence
of HCC after surgery in the present study, suggesting the ability
of CD24+ tumor cells to re-establish tumor growth. These data
support a previous study showing that CD24 is a useful predic-
tive marker for early recurrence of HBV-related HCC (Woo
et al., 2008). It has been predicted that T-ICs might also primarily
be responsible for the formation of tumor metastases (Dalerba
and Clarke, 2007). CD24 overexpression was also significantly
correlated with venous infiltration, which is an important clin-
ico-pathologic feature of HCC metastasis. Both in vitro and
in vivo data demonstrate that CD24+ HCC cells alone have the
capacity to initiate and sustain tumor growth, leading eventually
to cancer metastasis. Thus far, CD133 and EpCAM have been
identified as putative T-IC markers for HCC (Ma et al., 2007;
Yamashita et al., 2009). However, their metastatic potential has
not been investigated. By using flow cytometric analysis, we
found that CD24 expression overlapped with the expression of
both CD133 (90.9%) and EpCAM (55.8%), suggesting that
they may share common self-renewal pathways. However,
unlike CD24, CD133+ liver T-ICs have previously been found to
have a greater proliferative potential than CD133 counterparts
(Ma et al., 2007). We do not, at the moment, have an explanation
as to why CD24 and CD133 subpopulations display different60 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.proliferative potential, as demonstrated by colony formation
assay. Yet, we speculate that because CD24 expression does
not completely overlap with CD133 (9.1% CD24+CD133) and
EpCAM (44.2% CD24+EpCAM), it is possible that these T-IC
markersmay display different tumorigenic andmetastatic poten-
tials. In terms of their tumorigenic potential, 23 104 CD133+ and
1 3 104 EpCAM+ HCC cells derived from patient samples were
previously reported to be needed for efficient tumor formation
in immunodeficient mice (Ma et al., 2010; Yamashita et al.,
2009). And in our current study, we found that as few as 4000
CD24+ HCC cells were sufficient for consistent tumor initiation.
Unlike CD133 and EpCAM, CD24 showed only very low over-
lapping expression with CD90. Using aCD90 shRNA knockdown
approach, CD90-repressed clones or CD90-expressing clones
were sorted for CD24+ and CD24 cells. The tumorigenicity of
CD24+ CD90-expressing or knockdown cells were found to be
very similar, indicating that CD24 can serve as a unique function
in the T-ICs of HCC. In terms of metastatic potential, 5000 CD90+
liver T-ICs was previously reported to induce lung metastasis
after orthotropic injection in 50% of the animals examined
(Yang et al., 2008), whereas in our current study, we found that
only 4000 CD24+ liver T-ICs derived from patient samples was
sufficient to induce lung metastasis after subcutaneous injection
in 100% of the animals tested. These results demonstrate the
superiority of CD24 in some aspects over currently available liver
T-IC markers.
Using lentiviral-based RNA interference approach, CD24 was
found to be functional liver T-IC marker. Also, in an orthotopic
HCC tumor model, CD24 knockdown not only inhibited the
growth of tumors but also inhibited metastasis to the lungs of
SCID mice. Furthermore, we found that stemness genes such
as OCT4, SOX2, and NANOG were downregulated when CD24
was knocked down, suggesting a crosstalk between CD24
signaling and stemness gene expression. Interestingly, we found
a significant correlation between CD24 expression and NANOG
expression in a panel of HCC cell lines and HCC clinical samples.
NANOG is a self-renewal gene that maintains the pluripotency of
embryonic stem cells (Silva et al., 2009). Recently, NANOG was
identified as a new oncogene by large-scale oncogenomic anal-
ysis (Mattison et al., 2010), and NANOG expression regulates
human tumor development (Jeter et al., 2009). To determine
whether CD24 drove tumor initiation and self-renewal through
activation of NANOG gene expression, we overexpressed
NANOG in a CD24 knockdown clone (#278) of Huh-7 cells. We
found that the effect of CD24 knockdown was eliminated upon
transfection of NANOG, demonstrating that CD24 upregulates
NANOG expression to initiate tumor formation and self-renewal.
However, by western blot analysis, we found that CD24 expres-
sion did not change upon overexpression of NANOG and inhibi-
tion of STAT3 (data not shown). This indicates that NANOG and
STAT3 truly are downstream targets of CD24.
By cDNA microarray comparison of gene expression between
CD24 knockdown cells and control cells, we found that the IL6/
STAT3 pathway was significantly downregulated upon CD24
knockdown. The IL6/STAT3 pathway has been previously
demonstrated to play important roles in the maintenance and
proliferation of liver T-ICs (Lin et al., 2009; Tang et al., 2008).
CD24 is associated with Src-associated kinase (Sammar et al.,
1997), which phosphorylates STAT3 (Byers et al., 2009). By
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was consistently altered with phosphorylated STAT3 (Y705) and
NANOG expression, which suggests that CD24 might act on
STAT3 through Src. By ChIP assay, we found binding of phos-
phorylated STAT3 (Y705) to NANOG promoter, which is consis-
tent to the previous study shown in murine system (Suzuki et al.,
2006). Upon CD24 knockdown in Huh-7 and PLC/PRF/5, there
was reduced binding between phosphorylated STAT3 (Y705)
and NANOG promoter. By western blot analysis, we found that
less phosphorylated STAT3 (Y705) was observed in CD24
knockdown cells. It is controversial whetherNANOG is regulated
in a STAT3-dependent manner (Humphrey et al., 2004). NANOG
expression was found to be reduced in a dose-dependent
manner upon addition of S3I-201, indicating a regulatory role
of STAT3 on NANOG expression. With GFP as a reporter of
NANOG promoter activity, we found that CD24+ PLC cells
showed higher NANOG promoter activity, and this activity was
reduced upon addition of S3I-201. This result suggests that
CD24 activates NANOG promoter in a STAT3-dependent
manner.
Current chemotherapy against HCC usually primarily directs
against the bulk population of the tumor. Although these
therapies are able to initially shrink the primary tumors, they fail
to consistently eradicate the lesions, leading to tumor relapse.
In this study, we identified CD24+ HCC cells within these small
lesions, and they functioned to initiate tumor growth and self-
renewal through STAT3-mediated NANOG upregulation. The
identification of CD24 signaling pathways provides an attractive
therapeutic strategy against this deadly disease.
EXPERIMENTAL PROCEDURES
Human HCC Tissue Collection and Processing
Liver tumor and adjacent nontumor liver tissue specimens were collected
from six patients (patients #3, 36, 38, 51, 71, and 73) (ages 37–82) who
underwent hepatectomy for HCC between 2008 and 2010 in the Department
of Surgery, Queen Mary Hospital, Hong Kong, with Institutional Review
Board (IRB) approval. Tumor tissue from xenografts and fresh tumors was
minced into 1 mm3 cubes and incubated with Type IV Collagenase (Sigma,
St. Louis, MO) for 5–10 min at 37C. A single-cell suspension was obtained
by filtering the supernatant through a 100 mm cell strainer (BD Biosciences).
Cell viability was assessed by trypan blue exclusion staining and counting
with a hemocytometer. For fresh clinical tumors, removal of CD45+ cells
from within the tumor was done with a CD45 depletion kit (Miltenyi Biotech,
Germany).
Isolation of CD24+ and CD24– Populations by Flow Cytometry
and Magnetic Bead Cell Sorting
For magnetic cell sorting, cells were labeled with PE-conjugated CD24 anti-
body (clone ML5) (BD PharMingen, San Jose, CA) followed by anti-PE
microbeads (Miltenyi Biotec, Germany). Sorting was carried out with the
Miltenyi Biotec MACS Cell Separation Kit according to the manufacturer’s
instructions. Magnetic separation was performed up to three times to obtain
aCD24+ populationmore than 95%pure. Aliquots of CD24+ andCD24 sorted
cells were evaluated for purity with a FACSCalibur machine and CellQuest
software (BDBiosciences). For isolation of CD24+ andCD24 cell populations,
cells were stained with PE-conjugated CD24 antibody (BD Biosciences) and
with isotype-matched mouse immunoglobulin as a control. Samples were
analyzed and sorted on a BD FACSAria (BD Biosciences). For the positive
and negative populations, only the top 10% most brightly stained cells and
the bottom 10%most dimly stained cells were selected, respectively. Aliquots
of CD24+ and CD24 sorted cells were evaluated for purity with a FACSCalibur
machine and CellQuest software (BD Biosciences).In Vivo Tumorigenicity Experiments
Different numbers of cells were injected subcutaneously either into severe
combined immunodeficient (SCID)-beige or nonobese diabetic (NOD)/SCID
mice. For an orthotopic tumor model, approximately 15,000 PLC/PRF/5 cells
in 30 ml of culturemediumwere injected into the left liver lobe of the SCID-beige
mice by a method described previously (Fu et al., 1991). For those HCC cells
labeled with luciferase, imaging was performed with a Xenogen IVIS 100
cooled CCD camera (Xenogen, CA) on Day 40. The mice were given intraper-
itoneal injections with 200 ml of 15 mg/mL D-luciferin 15 min before imaging.
For imaging, the mice were placed in a light-tight chamber, the acquisition
time ranged from 3 s to 1 min, and pseudoimages of the emitted light in
photons/s/cm2/steradian superimposed over the gray-scale photographs of
the animal were taken.
Chemoresistant Tumor Model
Subcutaneous xenografts were established with the PLC/PRF/5 and Huh-7
HCC cell line. The animals used to test the treatment were 4- to 6-week-old
male athymic nude mice (BALB/c-nu/nu). Treatment was started once the
size of the xenograft reached approximately 4 mm in diameter. The mice
were randomly assigned into four groups, each consisting of three mice.
They were treated with cisplatin intraperitoneally every 4 days for 4 weeks at
either 1 mg/kg, 2 mg/kg, or 5 mg/kg.
Statistical Analyses
All statistical analyses were performed with the statistical software SPSS 17
for Windows (SPSS Inc., Chicago, IL). Fisher’s exact test was used to assess
the correlation between clinico-pathological parameters and CD24 overex-
pression for HCC patients. Student’s t or Mann-Whitney test was used for con-
tinuous data wherever appropriate. The survival curves were assessed by the
Kaplan-Meier method, and the statistical difference between two groups was
evaluated by log rank test. p values less than 0.05 were considered statistically
significant.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE28057.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
doi:10.1016/j.stem.2011.06.005.
ACKNOWLEDGMENTS
The authors would like to thank LKS Faculty of Medicine at The University of
Hong Kong for the Faculty Core Facility. The study was supported by Hong
Kong Research Grants Council Collaborative Research Fund (HKU 1/06C
and HKU 7/CRF/09). I.O.L.N. is Loke Yew Professor in Pathology.
Received: August 18, 2010
Revised: April 11, 2011
Accepted: June 7, 2011
Published: July 7, 2011
REFERENCES
Aguayo, A., and Patt, Y.Z. (2001). Nonsurgical treatment of hepatocellular
carcinoma. Semin. Oncol. 28, 503–513.
Al-Hajj, M. (2007). Cancer stem cells and oncology therapeutics. Curr. Opin.
Oncol. 19, 61–64.
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke,
M.F. (2003). Prospective identification of tumorigenic breast cancer cells.
Proc. Natl. Acad. Sci. USA 100, 3983–3988.Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc. 61
Cell Stem Cell
CD24+ Cells Drive Self-Renewal and Tumor FormationArii, S., Tanaka, J., Yamazoe, Y., Minematsu, S., Morino, T., Fujita, K., Maetani,
S., and Tobe, T. (1992). Predictive factors for intrahepatic recurrence of hepa-
tocellular carcinoma after partial hepatectomy. Cancer 69, 913–919.
Bertolini, G., Roz, L., Perego, P., Tortoreto,M., Fontanella, E., Gatti, L., Pratesi,
G., Fabbri, A., Andriani, F., Tinelli, S., et al. (2009). Highly tumorigenic lung
cancer CD133+ cells display stem-like features and are spared by cisplatin
treatment. Proc. Natl. Acad. Sci. USA 106, 16281–16286.
Byers, L.A., Sen, B., Saigal, B., Diao, L., Wang, J., Nanjundan, M., Cascone, T.,
Mills, G.B., Heymach, J.V., and Johnson, F.M. (2009). Reciprocal regulation of
c-Src and STAT3 in non-small cell lung cancer. Clin. Cancer Res. 15, 6852–
6861.
Carr, B.I. (2004). Hepatocellular carcinoma: Current management and future
trends. Gastroenterology 127 (5, Suppl 1), S218–S224.
Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J., and Maitland, N.J. (2005).
Prospective identification of tumorigenic prostate cancer stem cells. Cancer
Res. 65, 10946–10951.
Cram, D.S., McIntosh, A., Oxbrow, L., Johnston, A.M., and DeAizpurua, H.J.
(1999). Differential mRNA display analysis of two related but functionally
distinct rat insulinoma (RIN) cell lines: Identification of CD24 and its expression
in the developing pancreas. Differentiation 64, 237–246.
Dalerba, P., and Clarke, M.F. (2007). Cancer stem cells and tumor metastasis:
First steps into uncharted territory. Cell Stem Cell 1, 241–242.
Dalerba, P., Cho, R.W., and Clarke, M.F. (2007). Cancer stem cells: Models
and concepts. Annu. Rev. Med. 58, 267–284.
Fang, D., Nguyen, T.K., Leishear, K., Finko, R., Kulp, A.N., Hotz, S., Van Belle,
P.A., Xu, X., Elder, D.E., and Herlyn, M. (2005). A tumorigenic subpopulation
with stem cell properties in melanomas. Cancer Res. 65, 9328–9337.
Friel, A.M., Sergent, P.A., Patnaude, C., Szotek, P.P., Oliva, E., Scadden, D.T.,
Seiden, M.V., Foster, R., and Rueda, B.R. (2008). Functional analyses of the
cancer stem cell-like properties of human endometrial tumor initiating cells.
Cell Cycle 7, 242–249.
Fu, X.Y., Besterman, J.M., Monosov, A., and Hoffman, R.M. (1991). Models of
human metastatic colon cancer in nude mice orthotopically constructed by
using histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 88,
9345–9349.
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J.M., Schroeder, A., Sheehy, A.,
Buettner, R., Proia, D., Kowolik, C.M., Xin, H., et al. (2009). The JAK2 inhibitor
AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Cancer Cell 16, 487–497.
Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M.,
Bruns, C.J., andHeeschen, C. (2007). Distinct populations of cancer stem cells
determine tumor growth and metastatic activity in human pancreatic cancer.
Cell Stem Cell 1, 313–323.
Huang, L.R., and Hsu, H.C. (1995). Cloning and expression of CD24 gene in
human hepatocellular carcinoma: A potential early tumor marker gene corre-
lates with p53 mutation and tumor differentiation. Cancer Res. 55, 4717–4721.
Humphrey, R.K., Beattie, G.M., Lopez, A.D., Bucay, N., King, C.C., Firpo, M.T.,
Rose-John, S., and Hayek, A. (2004). Maintenance of pluripotency in human
embryonic stem cells is STAT3 independent. Stem Cells 22, 522–530.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J.
(2008). Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96.
Jeter, C.R., Badeaux, M., Choy, G., Chandra, D., Patrawala, L., Liu, C.,
Calhoun-Davis, T., Zaehres, H., Daley, G.Q., and Tang, D.G. (2009).
Functional evidence that the self-renewal gene NANOG regulates human
tumor development. Stem Cells 27, 993–1005.
Kassahun, W.T., Fangmann, J., Harms, J., Hauss, J., and Bartels, M. (2006).
Liver resection and transplantation in the management of hepatocellular
carcinoma: A review. Exp. Clin. Transplant. 4, 549–558.
Kristiansen, G., Denkert, C., Schlu¨ns, K., Dahl, E., Pilarsky, C., and
Hauptmann, S. (2002). CD24 is expressed in ovarian cancer and is a new inde-
pendent prognostic marker of patient survival. Am. J. Pathol. 161, 1215–1221.
Kristiansen, G., Winzer, K.J., Mayordomo, E., Bellach, J., Schlu¨ns, K., Denkert,
C., Dahl, E., Pilarsky, C., Altevogt, P., Guski, H., and Dietel, M. (2003). CD2462 Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc.expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 9,
4906–4913.
Kuvshinoff, B.W., and Ota, D.M. (2002). Radiofrequency ablation of liver
tumors: Influence of technique and tumor size. Surgery 132, 605–611, discus-
sion 611–612.
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes,
J., Minden, M., Paterson, B., Caligiuri, M.A., and Dick, J.E. (1994). A cell initi-
ating human acute myeloid leukaemia after transplantation into SCID mice.
Nature 367, 645–648.
Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M.,
Clarke, M.F., and Simeone, D.M. (2007). Identification of pancreatic cancer
stem cells. Cancer Res. 67, 1030–1037.
Lin, L., Amin, R., Gallicano, G.I., Glasgow, E., Jogunoori, W., Jessup, J.M.,
Zasloff, M., Marshall, J.L., Shetty, K., Johnson, L., et al. (2009). The STAT3
inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted
TGF-beta signaling. Oncogene 28, 961–972.
Liu, S., Dontu, G., and Wicha, M.S. (2005). Mammary stem cells, self-renewal
pathways, and carcinogenesis. Breast Cancer Res. 7, 86–95.
Llovet, J.M., and Bruix, J. (2003). Systematic review of randomized trials for
unresectable hepatocellular carcinoma: Chemoembolization improves
survival. Hepatology 37, 429–442.
Ma, S., Chan, K.W., Hu, L., Lee, T.K., Wo, J.Y., Ng, I.O., Zheng, B.J., andGuan,
X.Y. (2007). Identification and characterization of tumorigenic liver cancer
stem/progenitor cells. Gastroenterology 132, 2542–2556.
Ma, S., Lee, T.K., Zheng, B.J., Chan, K.W., and Guan, X.Y. (2008). CD133+
HCC cancer stem cells confer chemoresistance by preferential expression
of the Akt/PKB survival pathway. Oncogene 27, 1749–1758.
Ma, S., Tang, K.H., Chan, Y.P., Lee, T.K., Kwan, P.S., Castilho, A., Ng, I.O.,
Man, K., Wong, N., To, K.F., et al. (2010). miR-130b promotes CD133(+) liver
tumor-initiating cell growth and self-renewal via tumor protein 53-induced
nuclear protein 1. Cell Stem Cell 7, 694–707.
Marquardt, J.U., and Thorgeirsson, S.S. (2010). Stem cells in hepatocarcino-
genesis: Evidence from genomic data. Semin. Liver Dis. 30, 26–34.
Mattison, J., Kool, J., Uren, A.G., de Ridder, J., Wessels, L., Jonkers, J.,
Bignell, G.R., Butler, A., Rust, A.G., Brosch, M., et al. (2010). Novel candidate
cancer genes identified by a large-scale cross-species comparative oncoge-
nomics approach. Cancer Res. 70, 883–895.
O’Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. (2007). A human colon
cancer cell capable of initiating tumour growth in immunodeficient mice.
Nature 445, 106–110.
Pardal, R., Clarke, M.F., and Morrison, S.J. (2003). Applying the principles of
stem-cell biology to cancer. Nat. Rev. Cancer 3, 895–902.
Patrawala, L., Calhoun, T., Schneider-Broussard, R., Zhou, J., Claypool, K.,
and Tang, D.G. (2005). Side population is enriched in tumorigenic, stem-like
cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumor-
igenic. Cancer Res. 65, 6207–6219.
Pirruccello, S.J., and LeBien, T.W. (1986). The human B cell-associated
antigen CD24 is a single chain sialoglycoprotein. J. Immunol. 136, 3779–3784.
Sammar, M., Gulbins, E., Hilbert, K., Lang, F., and Altevogt, P. (1997). Mouse
CD24 as a signaling molecule for integrin-mediated cell binding: functional and
physical association with src-kinases. Biochem. Biophys. Res. Commun. 234,
330–334.
Silva, J., Nichols, J., Theunissen, T.W., Guo, G., van Oosten, A.L., Barrandon,
O., Wray, J., Yamanaka, S., Chambers, I., and Smith, A. (2009). Nanog is the
gateway to the pluripotent ground state. Cell 138, 722–737.
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and
Dirks, P.B. (2003). Identification of a cancer stem cell in human brain tumors.
Cancer Res. 63, 5821–5828.
Suzuki, A., Raya, A., Kawakami, Y., Morita, M., Matsui, T., Nakashima, K.,
Gage, F.H., Rodrı´guez-Esteban, C., and Izpisu´a Belmonte, J.C. (2006).
Nanog binds to Smad1 and blocks bone morphogenetic protein-induced
differentiation of embryonic stem cells. Proc. Natl. Acad. Sci. USA 103,
10294–10299.
Cell Stem Cell
CD24+ Cells Drive Self-Renewal and Tumor FormationTang, Y., Kitisin, K., Jogunoori, W., Li, C., Deng, C.X., Mueller, S.C., Ressom,
H.W., Rashid, A., He, A.R., Mendelson, J.S., et al. (2008). Progenitor/stem cells
give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl.
Acad. Sci. USA 105, 2445–2450.
Wang, M., Xiao, J., Shen, M., Yahong, Y., Tian, R., Zhu, F., Jiang, J., Du, Z., Hu,
J., Liu, W., and Qin, R. (2011). Isolation and characterization of tumorigenic
extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int. J.
Cancer 128, 72–81.
Woo, H.G., Park, E.S., Cheon, J.H., Kim, J.H., Lee, J.S., Park, B.J., Kim, W.,
Park, S.C., Chung, Y.J., Kim, B.G., et al. (2008). Gene expression-based recur-
rence prediction of hepatitis B virus-related human hepatocellular carcinoma.
Clin. Cancer Res. 14, 2056–2064.
Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang,W.,Wang, H.Y., Jia, H., Ye,
Q., Qin, L.X., Wauthier, E., et al. (2009). EpCAM-positive hepatocellularcarcinoma cells are tumor-initiating cells with stem/progenitor cell features.
Gastroenterology 136, 1012–1024.
Yang, Z.F., Ho, D.W., Ng, M.N., Lau, C.K., Yu, W.C., Ngai, P., Chu, P.W., Lam,
C.T., Poon, R.T., and Fan, S.T. (2008). Significance of CD90+ cancer stem cells
in human liver cancer. Cancer Cell 13, 153–166.
Yang, X.R., Xu, Y., Yu, B., Zhou, J., Li, J.C., Qiu, S.J., Shi, Y.H., Wang, X.Y.,
Dai, Z., Shi, G.M., et al. (2009). CD24 is a novel predictor for poor prognosis
of hepatocellular carcinoma after surgery. Clin. Cancer Res. 15, 5518–5527.
Yeung, T.M., Gandhi, S.C., Wilding, J.L., Muschel, R., and Bodmer, W.F.
(2010). Cancer stem cells from colorectal cancer-derived cell lines. Proc.
Natl. Acad. Sci. USA 107, 3722–3727.
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F.,
Lieberman, J., and Song, E. (2007). let-7 regulates self renewal and tumorige-
nicity of breast cancer cells. Cell 131, 1109–1123.Cell Stem Cell 9, 50–63, July 8, 2011 ª2011 Elsevier Inc. 63
